Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
Times cited: 2
Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma.
Journal of Clinical Oncology.
Times cited: 12